Demystifying the Relationship Between GLP-1s and Cancer

GLP-1s are among the most talked-about drugs on the market right now. But what do we actually know about how they relate to cancer risk? Join endocrinologist Dr. Josh Levine for a clear, evidence-based conversation that cuts through the noise, explaining what the current research does and doesn't tell us, and helping you understand what these findings may mean for you. 

Questions? Contact Becky Koren at [email protected].

Thank you to our webinar sponsor: Cooperative Agreement 24-0061 from the Centers for Disease Control and Prevention.

Speaker Bio

Dr. Josh Levine, is the product team lead for berobenatide, a novel GLP-1 receptor agonist in phase 3 testing at Pfizer.  He received his MD and PhD from Columbia University.  He then went on to complete his clinical training in Internal Medicine and Endocrinology at Northwestern University.  Josh was on faculty at Northwestern and shortly afterwards joined Eli Lilly to be the US launch lead for Mounjaro.  He joined Pfizer to run the phase 3 clinical trials in obesity including his current position on berobenatide.
 
In addition to his work at Pfizer, Josh maintains a clinical practice at Montefiore Medical Center in the Bronx seeing patients with endocrinology issues. Josh currently lives in Scarsdale NY with his wife Rebecca and children Jamie and Elizabeth. 

Disclaimer: By joining this program I understand and acknowledge that Sharsheret is not providing medical advice. Additionally, I release and waive Sharsheret from any liability in the event of any accident or injury I may incur either during the course of this webinar or in performing any of the activities discussed during the same.

All views shared on the webinar are of the speakers and are independent of the program sponsors. To the best knowledge of Sharsheret, no relationship exists between the sponsors and the speakers, and no payment has or will be made by the sponsor to the speakers in connection with this webinar.